Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS

NCT05538130 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05538130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05538130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 30, 2022
Completion date
August 31, 2027
Enrollment
148 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, brain neoplasms, differentiated thyroid cancer, glioma, hgg, high grade glioma, lgg, low grade glioma, malignant neoplasms, melanoma, non-small cell lung cancer, nsclc (non-small cell lung cancer), thyroid cancer